Intel
INTC
Broadcom
AVGO
Alibaba
BABA
NVIDIA
NVDA
Micron Technology
MU
US Stock MarketDetailed Quotes
MAIA MAIA Biotechnology
- 2.000
- -0.020-0.99%
Close Jan 17 16:00 ET
- 2.000
- 0.0000.00%
Post 20:01 ET
52.32MMarket Cap-1.49P/E (TTM)
2.100High1.990Low147.76KVolume2.020Open2.020Pre Close299.81KTurnover0.68%Turnover RatioLossP/E (Static)26.16MShares5.99052wk High32.26P/B43.29MFloat Cap1.24052wk Low--Dividend TTM21.64MShs Float9.640Historical High--Div YieldTTM5.45%Amplitude0.820Historical Low2.029Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
MAIA Biotechnology Stock Forum
$Biomea Fusion (BMEA.US)$ Covalent III Trial regarding Type 2 Diabetes mellitus out tomorrow 8AM ET. SI 44.16%. COH $62.4M good for 6.2 months
$Sidus Space (SIDU.US)$ Satellite launch Friday. May continue until launch. Low float. 0 shares LTB.COH $4.8M good for 4.2 months✅
$Maison Solutions (MSS.US)$ PR AH 12/...
Maia Biotechnology Granted FDA Rare Pediatric Disease Designation for Thio as a Treatment for Pediatric High-Grade Gliomas
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas
Monday, 16th December at 8:37 am
MAIA Biotechnology, Inc., (NYSE: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a "rare pediatric dis...
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...
MAIA Biotechnology Announces Private Placement of Approximately $950,000
MAIA Biotechnology (NYSE American: MAIA) has announced a private placement of 507,364 shares of common stock at $1.872 per share to accredited investors and company directors. Each share comes with a warrant to purchase one additional share at $2.08, exercisable after six months with a five-year term.
The placement is expected to raise approximately $950,000 in gross proceeds, closing aroun...
No comment yet